JPRN-UMIN000019876已完成1 期
A phase I/II study for the safety and efficacy of Panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy - A phase I/II study for the safety and efficacy of Panitumumab in combination with TAS-102 for patients with metastatic colorectal cancer (APOLLON study)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Has received anti-EGFR antibodies (cetuximab or panitumumab), regorafenib, or TAS-102. (2)Has had treatment with radiotherapy and/or chemotherapy within 2 weeks (14 days) prior to study drug administration (except for limited field radiation in order to rescue of pain). (3)Known brain metastasis or strongly suspected of brain metastasis (4)Synchronous cancers or metachronous cancers with a disease-free period of 5 years (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin cancer, bladder cancer, etc.). (5)Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial effusion, etc.) (6)Patients who do not want to use contraception to prevent pregnancy, and women who are pregnant or breast-feeding, or test positive for pregnancy (7)Any investigational agent received within prior 4 weeks (28 days). (8)Disease requiring systemic steroids for treatment (excluding topical steroids) (9)History or obvious and extensive CT findings of interstitial pulmonary disease (interstitial pneumonia, pulmonary fibrosis, etc.) (10)Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhoea (incapacitating symptoms despite adequate treatment. (11)Serious drug hypersensitivity (without allergy to oxaliplatin) (12)Local or systemic active infection requiring treatment, or fever indicating infection (13)NYHA class II or higher heart failure or serious heart disease (14)Active hepatitis B (15)Known HIV infection (16)Peripheral neuropathy of Grade 2 or greater by CTCAE (Japanese edition JCOG version 4.03) (17)Known BRAF mutation (18)Other patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study
研究者
相似试验
进行中（未招募）
不适用
A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients - GFM-Aza intensifEUCTR2010-020341-27-FRGroupe Francophone des Myélodysplasies
已完成
1 期
A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone and in Combination with 5-Fluorouracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell CarcinomaACTRN12615001017516Ascend Biopharmaceutical Ltd.16
招募中
不适用
Phase Ib/II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM)eye melanoma10030054ocular melanomaNL-OMON41385ederlands Kanker Instituut38
进行中（未招募）
1 期
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002184-97-FRCentre François Baclesse57
尚未招募
2 期
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy with duodenojejunal bypass for obesity with diabetes mellitusMorbid obesity with diabetes mellitusJPRN-UMIN000035537Kansai Medical University Hospital33